ALKERMES | ALKS - هزینه های اجرایی





هزینه های اجرایی تغییر دادن تاریخ
AbbVie USD 10.81B 13.45B 2025-12
Acadia Pharmaceuticals USD 266.6M 23.72M 2025-12
ALKERMES USD 326.44M 1.41B 2025-12
Amgen USD 5.9B 773M 2025-12
Biogen USD 1.88B 81.4M 2025-09
BioMarin Pharmaceutical USD 676.18M 131.65M 2025-12
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Coherus Biosciences USD 51.83M 2.48M 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
Heron Therapeutics USD 40.55M 1.46M 2025-12
Ionis Pharmaceuticals USD 418M 101.1M 2025-12
J&J USD 18.97B 2.38B 2025-12
Malin Corporation EUR 1.1M 400K 2024-12
Merck USD 10.16B 558M 2025-12
Minerva Neurosciences USD 4.52M 155.46K 2024-12
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
Otsuka Holdings JPY 582.9B 113.74B 2025-12
Ovoca Bio EUR 1.16M 4.48M 2025-06
Pfizer USD 12.91B 79.89B 2025-12
Regeneron Pharmaceuticals USD 2.99B 27.97B 2025-12
Vertex Pharmaceuticals USD 1.93B 89.1M 2025-12